Intelligence · Clinical pipeline
Oncology · Phase II
Oncology programs at Phase II — ClinicalTrials.gov pipeline intelligence.
Quick answer
Oncology Phase II programs: NovaPharmaNews indexes 2,637 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.
Top sponsors
- First People's Hospital 261 programs
- Chinese Academy of 198 programs
- George Institute for 118 programs
- United Therapeutics Europe 112 programs
- Telethon Foundation 91 programs
- Takeda 79 programs
- Regeneron UK 71 programs
- MSD Merck Sharp 63 programs
- Ningbo Cancer Hospital 62 programs
- Anaxis Pharma 57 programs
- AstraZeneca 52 programs
- HOFFMANN-LA ROCHE 50 programs
Pipeline programs
-
Expanded , Activated NK cells
Hospital Authority, Hong Kong
Ewing Sarcoma
1 trial -
Experimental
The First People's Hospital of Lianyungang
Locally Advanced Rectal Cancer (LARC)
1 trial -
Experimental: tislelizumab+anlotinib
The First People's Hospital of Lianyungang
Thymic Carcinoma
1 trial -
Extended-release Onapristone
Context Therapeutics
Refractory Endometrial Adenocarcinoma
1 trial -
F-FR-60000-023
Ipsen
Unresectable, Locally Advanced or Metastatic Renal Cell Carcinoma with a Clear-Cell Component Who Progressed After 1st Line Treatment with Checkpoint Inhibitors
1 trial -
F60087CI101
Pierre Fabre Medicament
locally advanced or metastatic non-small cell lung cancer (NSCLC) resistant to EGFR tyrosine kinase inhibitors (TKIs)
1 trial -
FCN-437c+Fulvestrant
The First People's Hospital of Lianyungang
Breast Neoplasms
1 trial -
FDC fianlimab+cemiplimab
Regeneron UK Limited
Head and Neck Squamous Cell Carcinoma (HNSCC)
1 trial -
FEMH-95011
Hospital Authority, Hong Kong
Stomach Neoplasms
1 trial -
FFCD 1605 OPTIPRIME
CERO THERAPEUTICS HOLDINGS, INC.
metastatic colorectal adenocarcinoma
1 trial -
FFCD 1709 - SIRTCI
CERO THERAPEUTICS HOLDINGS, INC.
microsatellite stable (MSS) colorectal cancer with liver-dominant metastasis
1 trial -
FFCD 2006 NEORAF
CERO THERAPEUTICS HOLDINGS, INC.
BRAF V600E-MUTATED LOCALISED COLON OR UPPER RECTUM CANCER
1 trial -
FFCD1703
CERO THERAPEUTICS HOLDINGS, INC.
MICROSATELLITE STABLE (MSS) METASTATIC COLORECTAL CANCER AND A HIGH IMMUNE INFILTRATE
1 trial -
FGF401
Novartis Pharmaceuticals
Hepatocellular Carcinoma (HCC)
1 trial -
FHD-286
Foghorn Therapeutics
Small Cell Lung Cancer
1 trial -
FIL_COLUMN
Fondazione Telethon ETS
Mantle cell lymphoma
1 trial -
FIL_MOZART
Fondazione Telethon ETS
Follicular lymphoma
1 trial -
FIL_RI-CHOP
Fondazione Telethon ETS
Diffuse Large B-cell Lymphoma ABC
1 trial -
FIL_V-RBAC
Fondazione Telethon ETS
Mantle Cell Lymphoma
1 trial -
FOG-001
Parabilis Medicines
Cancer
1 trial -
FOLFIRI
Eisai Co.,
Colon Cancer
1 trial -
FOLFIRI regimen
Cardiff Oncology
Colorectal Cancer
1 trial -
FOLFIRNINOX
ACTUATE THERAPEUTICS, INC.
Pancreatic Adenocarcinoma
1 trial -
FOLFOX/FOLFIRI
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Unresectable or Metastatic Colorectal Cancer
1 trial -
FOLFOXIRI
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Colon Cancer
1 trial -
FOLFOXIRI-based HAIC+Fuquinitinib
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Colorectal Neoplasms
1 trial -
FP-1039
Prime Medicine
Endometrial Cancers With FGFR2 Mutations
1 trial -
FRUZAQLA hard capsules for métastatique colorectal cancer
CERO THERAPEUTICS HOLDINGS, INC.
métastatique colorectal cancer
1 trial -
FRα peptide plus Adjuvant (GM-CSF)
Marker Therapeutics
Platinum Sensitive Ovarian Cancer
1 trial -
FULVESTRANT for advanced breast cancer
The George Institute
advanced breast cancer
1 trial -
FUTURE
The George Institute
Colorectal cancer
1 trial -
FWD1802
Forward Pharmaceuticals Co.,
Metastatic Breast Cancer
1 trial -
Famitinib
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Non-Small Cell Lung Cancer (NSCLC)
1 trial -
Fentanyl
Teva Pharma GmbH
Cancer
1 trial -
Fentanyl Buccal Tablet
Teva Pharma GmbH
Advanced Cancers
1 trial -
Fianlimab
Regeneron UK Limited
Advanced Melanoma
1 trial -
Fianlimab
Regeneron UK Limited
Advanced Renal Cell Carcinoma (aRCC)
1 trial -
Fianlimab
Regeneron UK Limited
Resectable Non-small Cell Lung Cancer
1 trial -
Fianlimab+cemiplimab
Regeneron UK Limited
Melanoma
1 trial -
Fibromun, Darleukin
Philogen S.p.A.
Patients with locally advanced Basal Cell Carcinoma (LaBCC) amenable to intratumoral injection, who have progressed or intolerant to systemic treatment.
1 trial -
Fibromun, Darleukin
Philogen S.p.A.
Cutaneous Squamous Cell Carcinoma
1 trial -
Fibromun, Darleukin
Philogen S.p.A.
Phase II, open label, multicentric, proof-of-principle basket trial in patients with malignant tumors of the skin amenable to intratumoral injection, and in a curative or neoadjuvant or palliative intention, including: • Basal cell carcinoma (BCC) • Cutaneous squamous cell carcinoma (cSCC) • Merkel cell carcinoma (MCC) • Keratoacanthoma (KA) • Malignant adnexal tumors of the skin (MATS) • Tumors from cutaneous T-cell lymphoma (CTCL) • Kaposi’s sarcoma (KS)
1 trial -
Ficerafusp alfa
Bicara Therapeutics
Head and Neck Squamous Cell Carcinoma (HNSCC)
1 trial -
Ficerafusp alfa
Bicara Therapeutics
Squamous Cell Carcinoma of Head and Neck (SCCHN)
1 trial -
First-line Cohort
The First People's Hospital of Lianyungang
Hepatocellular Carcinoma (HCC)
1 trial -
FirstHCMU-JBi-PARTOM
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Metastatic Castration-resistant Prostate Cancer
1 trial -
Fluciclovine F18
Telix Innovations
Prostate Adenocarcinoma
1 trial -
Fludarabina Accord /ml concentrado para soluc...
The George Institute
Refractary or relapse non-Hodgkin T CD30+ lymphoma., Refractary or relapse Hodgkin T CD30+ lymphoma
1 trial
Frequently asked questions
How many oncology Phase II programs exist?
2,637 programs match both the therapeutic area and stage filters in our published index.